Journal article

Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses

Jessica Da Gama Duarte, Katherine Woods, Luke T Quigley, Cyril Deceneux, Candani Tutuka, Tom Witkowski, Simone Ostrouska, Chris Hudson, Simon Chang-Hao Tsao, Anupama Pasam, Alexander Dobrovic, Jonathan M Blackburn, Jonathan Cebon, Andreas Behren

CANCERS | MDPI | Published : 2021

Abstract

Antibodies that block immune regulatory checkpoints (programmed cell death 1, PD-1 and cytotoxic T-lymphocyte-associated antigen 4, CTLA-4) to mobilise immunity have shown unprecedented clinical efficacy against cancer, demonstrating the importance of antigen-specific tumour recognition. Despite this, many patients still fail to benefit from these treatments and additional approaches are being sought. These include mechanisms that boost antigen-specific immunity either by vaccination or adoptive transfer of effector cells. Other than neoantigens, epigenetically regulated and shared antigens such as NY-ESO-1 are attractive targets; however, tissue expression is often heterogeneous and weak. T..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Cure Cancer Australia through the Cancer Australia Priority-driven Cancer Research Scheme


Funding Acknowledgements

This project was partially funded by a Clinical and Laboratory Integration Program (CLIP) grant from the Cancer Research Institute (CRI). This project was also funded in part by the Ludwig Institute for Cancer Research, Melanoma Research Alliance (MRA) and the Melbourne Research Victoria (MRV). The Olivia Newton-John Cancer Research Institute acknowledges the support of the Victorian Government Operational Infrastructure Support Program and the Ian Potter Foundation for providing funds to purchase the Vectra System. The contents of the published material are solely the responsibility of La Trobe University and do not reflect the views of Cancer Australia. J.D.G.D. is supported by Cure Cancer Australia through the Cancer Australia Priority-driven Cancer Research Scheme (#1187815). J.M.B. is supported by a research chair from the National Research Foundation (South Africa). A.B. is supported by a fellowship from the Department of Health and Human Services acting through the Victorian Cancer Agency (VCA).